Literature DB >> 29510454

Needle electromyography practice patterns in patients taking novel oral anticoagulants: A survey-based study.

Ikjae Lee1, Hani Kushlaf2.   

Abstract

INTRODUCTION: This study sought to evaluate needle electromyography (EMG) practice patterns among electromyographers with patients taking novel oral anticoagulants (NOAC).
METHODS: A survey questionnaire was sent to members of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) via email web link. Anonymous survey responses were collected through an online website.
RESULTS: Fifty-eight AANEM members responded, 28 (48%) of whom worked at a teaching hospital and 30 (52%) of whom worked in a private setting. Fifty-four (93%) responders perform needle EMG on patients taking NOACs. Twenty-nine (50%) responders examine paraspinal muscles, and 20 (40%) responders examine facial muscles. Among 14 responders who perform single-fiber EMG (SFEMG), 8 examine patients taking NOACs. DISCUSSION: Although most of the electromyographers perform needle EMG on patients taking NOACs, they reported variable practice patterns in examination of the paraspinal and facial muscles and in performing SFEMG. A prospective risk-benefit study is required. Muscle Nerve 58: 307-309, 2018.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  EMG; NOAC; bleeding complication; needle electromyography; novel oral anticoagulant; survey

Mesh:

Substances:

Year:  2018        PMID: 29510454     DOI: 10.1002/mus.26119

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Needle EMG induced muscle bleeding complication after guideline approved discontinuation of anticoagulation.

Authors:  Michael Bartl; Arne Krahn; Joachim Riggert; Walter Paulus
Journal:  Clin Neurophysiol Pract       Date:  2021-03-26

Review 2.  Dry Needling and Antithrombotic Drugs.

Authors:  María Muñoz; Jan Dommerholt; Sara Pérez-Palomares; Pablo Herrero; Sandra Calvo
Journal:  Pain Res Manag       Date:  2022-01-07       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.